Sk Bio Pharmaceutical logo

Sk Bio Pharmaceutical

SK Biopharmaceuticals is a speciality pharma company, involved in the development of drugs for the treatment of neurological and metabolic disorders.

In 2011, SK Biopharmaceuticals was spunned off from SK holdings life science with an idea of commercializing neurology products from a new entity, with an exclusive focuse on neuroproducts.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.skbp.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
99,Seorin-dong, Jongno-gu Seoul 110-110
Seoul
South Korea
Email
Contact Number

Key parteners include Aribio pharmaceuticals, Jazz Pharma, Hanmi pharmaceuticals, Medicilon and PKU healthcare Group.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In 2012, Hanmi Pharmacutical acquired regional marketing rights for SK Biopharmaceuticals diazepam nasal spray (DZNS) technology for Korea and China for an upfront payment, development and sales milestones, and royalties on sales in return.

In Jan 2018, SK BioPharm established a joint venture with Glycyx Therapeutics Ltd and Relenopride to develop the drug as a treatment for rare neurological diseases.

In Dec 2016, SK BioPharm entered into a joint research agreement on the development of a new drug for brain tumor with brain cancer research center with Samsung Medical Center, Samsung Medical Center.